Haemophilia A

Haemophilia is an inherited bleeding disorder in which a person’s blood does not clot properly, which in some cases can lead to prolonged bleeding, either spontaneously or after trauma.1 In a third of cases, Haemophilia appears in individuals with no family history of the disorder.2

Haemophilia A is the most common form of Haemophilia. Left untreated, bleeds can lead to permanent joint and muscle damage1.

For more than 20 years, Roche has been innovating and delivering medicines for people with diseases of the blood.

Globally, we are working closely with partners in the haemophilia community to help ensure that people living with haemophilia A can access appropriate treatment and support at all stages of their journey.

Roche Australia is a proud supporter of the Australian Haemophilia community through the Haemophilia Foundations Australia (HFA) and through educational initiatives for the healthcare community to support the quality use of medicines.

Globally, we are collaborating with the World Federation of Hemophilia (WFH) to support treatment of people living with haemophilia A in locations where there is little or no access to haemophilia treatment.

In addition, Roche contributes to the WFH Humanitarian Aid Program integrated care development training, with funding to ensure local infrastructure and medical expertise are available to optimise and appropriately use the donated products.3

By working toward a shared vision of Treatment for All, the WFH and all of its partners, including Roche, aim to address gaps in healthcare and bring innovative treatment solutions to people living with haemophilia.